Author

Dorothée Bouron Dal Soglio

Centre Hospitalier Universitaire Sainte-Justine

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Genetics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:organoid / primary culture· 1 Research Focus:trajectory inference· 1

Frequent Co-Authors

Massimiliano PaganelliiD· 2 shared Basma Benabdallah· 1 shared C. Casini RaggiiD· 1 shared Chenicka Lyn Mangahas· 1 shared Christian M. BeausejouriD· 1 shared Claudia Goupil· 1 shared Denis CyriD· 1 shared Élie HaddadiD· 1 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

Massimiliano PaganelliORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioengineeringbioRxivPreprintOct 8, 2025

Off-the-Shelf Engineered Liver Tissue Reverses Acute Liver Failure Without Immunosuppression

C. Casini Raggi, Pascal Lapierre, Marie-Agnès M’Callum…·Massimiliano Paganelli

This paper describes engineered liver tissue that reverses acute liver failure in mice without immunosuppression, demonstrating potential for clinical translation.

DOI 10.1101/2025.10.08.680796

mouseorganoid / primary culture

𝕏 PostBluesky

GeneticsbioRxivPreprintSep 29, 2023

In vivo dissection of the mouse tyrosine catabolic pathway with CRISPR-Cas9 identifies modifier genes affecting hereditary tyrosinemia type 1

Jean-François Rivest, Sophie Carter, Claudia Goupil…·Yannick Doyon

The paper uses CRISPR-Cas9 in mice to identify modifier genes that affect the severity of tyrosinemia type 1 by editing enzymes in the tyrosine catabolic pathway.

DOI 10.1101/2023.09.29.559947

mouseexperimental assay

𝕏 PostBluesky